Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
J Med Chem ; 58(22): 8877-95, 2015 Nov 25.
Artículo en Inglés | MEDLINE | ID: mdl-26455919

RESUMEN

Because of their increased activity against activating mutants, first-generation epidermal growth factor receptor (EGFR) kinase inhibitors have had remarkable success in treating non-small-cell lung cancer (NSCLC) patients, but acquired resistance, through a secondary mutation of the gatekeeper residue, means that clinical responses only last for 8-14 months. Addressing this unmet medical need requires agents that can target both of the most common double mutants: T790M/L858R (TMLR) and T790M/del(746-750) (TMdel). Herein we describe how a noncovalent double mutant selective lead compound was optimized using a strategy focused on the structure-guided increase in potency without added lipophilicity or reduction of three-dimensional character. Following successive rounds of design and synthesis it was discovered that cis-fluoro substitution on 4-hydroxy- and 4-methoxypiperidinyl groups provided synergistic, substantial, and specific potency gain through direct interaction with the enzyme and/or effects on the proximal ligand oxygen atom. Further development of the fluorohydroxypiperidine series resulted in the identification of a pair of diastereomers that showed 50-fold enzyme and cell based selectivity for T790M mutants over wild-type EGFR (wtEGFR) in vitro and pathway knock-down in an in vivo xenograft model.


Asunto(s)
Antineoplásicos/síntesis química , Antineoplásicos/farmacología , Receptores ErbB/antagonistas & inhibidores , Genes erbB-1/efectos de los fármacos , Animales , Antineoplásicos/farmacocinética , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Línea Celular Tumoral , Perros , Diseño de Fármacos , Técnicas de Silenciamiento del Gen , Humanos , Técnicas In Vitro , Lípidos/química , Neoplasias Pulmonares/tratamiento farmacológico , Macaca fascicularis , Microsomas Hepáticos/metabolismo , Modelos Moleculares , Mutación , Ratas , Estereoisomerismo , Relación Estructura-Actividad , Especificidad por Sustrato , Ensayos Antitumor por Modelo de Xenoinjerto
3.
J Org Chem ; 67(24): 8610-7, 2002 Nov 29.
Artículo en Inglés | MEDLINE | ID: mdl-12444645

RESUMEN

Several alpha-substituted N-carbethoxytropinones have been evaluated as catalysts for asymmetric epoxidation of alkenes with Oxone, via a dioxirane intermediate. alpha-Fluoro-N-carbethoxytropinone (2) has been studied in detail and is an efficient catalyst which does not suffer from Baeyer-Villiger decomposition and can be used in relatively low loadings. This ketone was prepared in enantiomerically pure form using chiral base desymmetrization of N-carbethoxytropinone. Asymmetric epoxidation catalyzed by 2 affords epoxides with up to 83% ee. Among other derivatives tested, the alpha-acetoxy derivative 7 affords the highest enantioselectivities.

4.
J Org Chem ; 68(8): 3232-7, 2003 Apr 18.
Artículo en Inglés | MEDLINE | ID: mdl-12688795

RESUMEN

The dioxirane-mediated epoxidation of alkenes in the presence of supported alpha-fluorotropinones 5 and 9 has been evaluated. The catalysts anchored onto silica supports 5 have shown comparable activity with respect to the homogeneous counterpart 10 and good stability on recycling. In the second part of this paper the enantiomerically enriched alpha-fluorotropinone 4 was anchored onto both mesoporous MCM-41 and amorphous KG-60 silicas. The chiral-supported catalysts promoted the stereoselective epoxidation of several trans-substituted and trisubstituted alkenes with ee values up to 80% and were perfectly reusable with the same performance for at least three catalytic cycles.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA